Mettler Toledo Head of Process Analytics Sold Shares Worth Over $754K

Mettler Toledo's Head of Process Analytics, Keller Gerry, sold 435 shares at $1,734.05 each, totaling $754,313. Gerry now directly owns 259 shares, according to an SEC filing.

Original reporting
Published Nov 10, 2026, 6:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mettler Toledo Head of Process Analytics Sold Shares Worth Over $754K — source image
Decision brief

The 30-second read

$MTDBearishLow
01

Why it matters

Insider sell may prompt short sellers; however, size is modest relative to market cap.

02

Market read

Small insider sale with limited market impact.

03

What to watch

Potential tax planning or portfolio rebalancing may drive the sale.

Relevance 4/10Novelty 4/10Timing: after-hours filing

Background

Form 4 filing by a senior executive of Mettler Toledo.

Company-level read

Ticker impact

$MTDBearishMedium confidence
Context

Head of Process Analytics sold 435 shares for $754,313, reducing his stake to 259 shares.

Expected impact

likely pressure as investors price in the insider sale

Evidence & confidence

Form 4 filing shows a material insider reducing position; such sales often lead to short-term downside.

Market effects

Minimal impact on industrial instrumentation sector.

US market only.

Low

Counterpoint

The sale could be unrelated to company outlook; no change in fundamentals.

Key entities

  • Keller Gerry

    Head of Process Analytics at Mettler Toledo

Related articles

$MTDHighAI 8/10

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway?

Mettler-Toledo's stock rose 25% despite biotech funding freeze. Management's 2026 EPS guidance of $47.70-$47.90 exceeds consensus, with 2027 guidance also above expectations. Analysts' average price target is $1,590, but some, like Jefferies, raised targets to $1,930. The company expects $900M in free cash flow, supporting an $875M share buyback. Growth drivers include pharmacopeia revisions and GLP-1 manufacturing. Investors should evaluate service revenue and hardware cycles.

$MTDMed

Biotech funding froze. Why has this lab instrument maker climbed 25% anyway? By Investing.com RSS CTA

Mettler-Toledo International (MTD) has risen 25.2% in two months, defying a biotech funding slowdown. The company, a key supplier of precision lab instruments, benefits from regulatory requirements in commercial drug production. Q3 results showed $1.09B revenue, $12.57 adjusted EPS, and strong margins. Management's 2026-2027 EPS guidance exceeds Wall Street estimates, with free cash flow supporting share buybacks.

$MTDMedAI 8/10

What Mettler-Toledo International (MTD) Said on Its Q3 Earnings Call

Mettler-Toledo (MTD) reported Q3 gross margin expansion to 59.8% and adjusted operating profit growth of 8%. The company raised its 2026 sales growth forecast to 5% and issued 2027 guidance, expecting 5% sales growth and adjusted EPS of $52.50-$53.50. Management highlighted opportunities in automation, digitalization, and U.S. onshoring, with potential upside from AI-driven instrument upgrades.

$MTDMed

Jefferies raises Mettler-Toledo stock price target on solid growth

Jefferies raised its price target for Mettler-Toledo (MTD) to $1,930, citing strong Q3 results with 6% local currency growth and improved 2026 outlook. The stock trades near its 52-week high, up 26.5% in six months. MTD reported Q3 adjusted earnings of $12.57 per share and revenue of $1.09 billion, both exceeding estimates. The company provided initial 2027 guidance with 5% growth and EPS of $52.50-$53.50, above consensus.